Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 1/2016

01-01-2016 | Review

Immunotherapies for Immune-Mediated Myopathies: A Current Perspective

Authors: Merrilee Needham, Frank L. Mastaglia

Published in: Neurotherapeutics | Issue 1/2016

Login to get access

Summary

Until recently, the treatment of immune-mediated inflammatory myopathies has largely been empirical with glucocorticoids, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin. However, a proportion of patients are only partially responsive to these therapies, and there has been a need to consider alternative treatment approaches. In particular, patients with inclusion body myositis are resistant to conventional immunotherapies or show only a transient response, and remain a major challenge. With increasing recognition of the different subtypes of immune-mediated inflammatory myopathies, and improved understanding of their pathogenesis, more targeted treatments are now being trialled. The overall approach to treatment, and novel therapies targeting B cells, T cells, and specific cytokines are discussed in this review.
Appendix
Available only for authorised users
Literature
1.
2.
Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012;11:203-206.PubMedCrossRef
3.
Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015;1852:622-632.
4.
Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014;178:405-415.PubMedPubMedCentralCrossRef
5.
Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-631.PubMedCrossRef
6.
Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006;2:219-227.PubMedCrossRef
7.
van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. J Neurol 2014;261:992-998.PubMedCrossRef
8.
Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-249.CrossRef
9.
Pestronk A, Kos K, Lopate G, Al-Lozi MT. Brachio-cervical inflammatory myopathies: clinical, immune, and myopathologic features. Arthritis Rheum 2006;54:1687-1696.PubMedCrossRef
10.
Rojana-Udomsart A, Fabian V, Hollingsworth PN, Walters SE, Zilko PJ, Mastaglia FL. Paraspinal and scapular myopathy associated with scleroderma. J Clin Neuromuscul Dis 2010;11:213-222.PubMedCrossRef
11.
Allenbach Y, Benveniste O. Diagnostic utility of auto-antibodies in inflammatory muscle disease. J Neuromuscul Dis 2015;2:13-25.
12.
13.
Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-418.PubMedCrossRef
14.
Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.PubMedCrossRef
15.
Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2015 Feb 24 [Epub ahead of print].
16.
Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988;23:493-499.PubMedCrossRef
17.
Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-2910.PubMedPubMedCentralCrossRef
18.
Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophy Acta 2015;1852:658-666.
19.
De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009;21:610-616.PubMedCrossRef
20.
Fasth AE, Dastmalchi M, Rahbar A, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009;183:4792-4799.PubMedCrossRef
21.
Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000;123:2030-2039.PubMedCrossRef
22.
Benveniste O, Herson S, Salomon B, et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 2004;56:867-872.PubMedCrossRef
23.
Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis Neurology 2007;69:1672-1679.PubMedCrossRef
24.
Van de Vlekkert J, Hoogendiijk JE, de Visser M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul Disord 2015;25:451-456.PubMedCrossRef
25.
Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008-2019.PubMedCrossRef
26.
27.
Mescam-Mancini L, Allenbach Y, Hervier B, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 2015;138:2485-2492.PubMedCrossRef
28.
Pestronk A. Immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2014;23:595-604.CrossRef
29.
Stenzel W, Goebel HH, Aronica E. Review: immune-mediated necrotizing myopathies—a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 2012;38:632-646.PubMedCrossRef
30.
Preusse C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012;181:2161-2171.PubMedCrossRef
31.
Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200.PubMedCrossRef
32.
Rodriguez Cruz PM, Luo YB, Miller J, Junckerstorff RC, Mastaglia FL, Fabian V. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 2014;24:1025-1035.PubMedCrossRef
33.
Rojana-udomsart A, Mitrpant C, Bundell C, et al. Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol 2013;264:65-70.PubMedCrossRef
34.
Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 2006;16:223-236.PubMedCrossRef
35.
Moran EM, Mastaglia FL. The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord 2014;24:943-952.PubMedCrossRef
36.
Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131:1228-1240.PubMedPubMedCentralCrossRef
37.
Mastaglia F. What to do when the treatment does not work: polymyositis. Pract Neurol 2008;2008:170-174.
38.
39.
Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve 1997;20:651-664.PubMedCrossRef
40.
Mastaglia FL, Phillips BA, Zilko PJ. Inflammatory myopathy. Curr Treat Options Neurol 1999;1:263-272.PubMedCrossRef
41.
Mastaglia FL, Zilko PJ. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 2003;10:99-101.PubMedCrossRef
42.
van de Vlekkert J, Hoogendijk JE, de Haan RJ, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010;20:382-389.PubMedCrossRef
43.
Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;8:CD003643.PubMed
44.
45.
Ikezoe K, Ohshima S, Osoegawa M, et al. Expression of granulysin in polymyositis and inclusion-body myositis. J Neurol Neurosurg Psychiatry 2006;77:1187-1190.PubMedCrossRefPubMedCentral
46.
Zong M, Jorholt J, Winter J, Lindroos E, Harris H, IL. Autophagy may contribute to glucocorticoid resistance in myositis patients by maintaining muscle T cells homeostasis. Ann Rheum Dis 2014;73(Suppl 1):A85-86.
47.
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.PubMedCrossRef
48.
Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998;51:S37-S45.PubMedCrossRef
49.
50.
Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-716.PubMedCrossRef
51.
Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.PubMedCrossRef
52.
Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28.PubMedCrossRef
53.
Albayda J, Mammen AL. Is statin-induced myositis part of the polymyositis disease spectrum? Curr Rheumatol Rep 2014;16:433.PubMedCrossRef
54.
Mosca M, Strigini F, Carmignani A, D'Ascanio A, Genazzani AR, Bombardieri S. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum 2005;53:119-121.PubMedCrossRef
55.
Ahmed AR, Gurcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2011;25:1073-1079.PubMedCrossRef
56.
Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012;22:382-393.PubMedCrossRef
57.
Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10:144-149.PubMedCrossRef
58.
Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J 2014;16:646-647.PubMed
59.
Marie I, Menard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011;41:48-60.PubMedCrossRef
60.
Frikha F, Rigolet A, Behin A, Fautrel B, Herson S, Benveniste O. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology 2009;48:1166-1168.PubMedCrossRef
61.
Lambotte O, Kotb R, Maigne G, Blanc F-X, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-1370.PubMed
62.
Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 2009;15:338-340.PubMedCrossRef
63.
Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005;11:264-266.PubMedCrossRef
64.
Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-3111.PubMedCrossRef
65.
Couderc M, Gottenberg J-E, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 2011;50:2283-2289.PubMedCrossRef
66.
Haroon M, Devlin J. Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 2012;32:1783-1784.PubMedCrossRef
67.
Feist E, Dorner T, Sorensen H, Burmester G-R. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008;35:1230-1232.PubMed
68.
Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-1868.PubMed
69.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-324.PubMedPubMedCentralCrossRef
70.
Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatal 2013;31:896-903.
71.
Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology 2009;48:594-595.PubMedCrossRef
72.
Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-767.PubMedCrossRef
73.
Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-749.PubMedPubMedCentralCrossRef
74.
75.
Thompson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008;35:2080-2082.PubMedCrossRef
76.
Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis-a case-based review. Clin Rheumatol 2015;34:609-612.PubMedCrossRef
77.
Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011;78:431-432.PubMedCrossRef
78.
Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012;160:520-522.PubMedPubMedCentralCrossRef
79.
Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 2000;19:352-359.PubMedCrossRef
80.
Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology 2005;44:562-563.PubMedCrossRef
81.
Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007;26:1186-1188.PubMedCrossRef
82.
Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-1236.PubMedPubMedCentralCrossRef
83.
Hengstman GJD, van den Hoogen FHJ, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-15.PubMedCrossRef
84.
Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology 2004;43:531-532.PubMedCrossRef
85.
Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology 2004;43:1198-1199.PubMedCrossRef
86.
Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology 2004;43:524-526.PubMedCrossRef
87.
Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010;29:563-566.PubMedCrossRef
88.
Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003;42:1566-1568.PubMedCrossRef
89.
Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 2006;16:410-411.PubMedCrossRef
90.
Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146:780-784.PubMedPubMedCentral
91.
Hengstman GJD, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59:159-163.PubMedCrossRef
92.
Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-1677.PubMedCrossRef
93.
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33:1802-1804.PubMed
94.
Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70:427-436.CrossRef
95.
Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-874.PubMedCrossRef
96.
Dorph C, Dastmalchi M, Alexanderson H, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014;73:913-920.PubMedCrossRef
97.
Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24:73-79.PubMedCrossRef
98.
Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990;4:2860-2867.PubMed
99.
Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 2011;50:1344-1346.PubMedCrossRef
100.
Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011;23:273-277.PubMedCrossRef
101.
Kaly L, Rosner I. Tocilizumab—a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012;26:157-165.PubMedCrossRef
102.
Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009;60:2505-2512.PubMedCrossRef
103.
Kazuki T, Bookbinder S, Furie R. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Res 2002;46:S489.CrossRef
104.
105.
106.
Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73:256-262.PubMedCrossRef
107.
Fiechtner J, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus 2014;23:905-912.PubMedPubMedCentralCrossRef
108.
Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004;56:1-29.PubMedCrossRef
109.
Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012;6:133-139.PubMedCrossRef
110.
Henes JC, Heinzelmann F, Wacker A, et al. Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation. Ann Rheum Dis 2009;68:447-448.PubMedCrossRef
111.
Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010;39:88-92.PubMedCrossRef
112.
Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011;70:1285-1288.PubMedCrossRef
113.
Cherin P, Auperin I, Bussel A, Pourrat J, Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol 1995;13:270-271.PubMed
114.
Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384.PubMedCrossRef
115.
Pons-Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011;10:679-684.PubMedCrossRef
116.
Azali P, Barbasso Helmers S, Kockum I, et al. Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis 2013;72:512-516.PubMedCrossRef
117.
Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011;70:1569-1574.PubMedCrossRef
118.
Cutolo M. Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann Rheum Dis 2013;72:473-475.PubMedCrossRef
119.
Di Luigi L, Sottili M, Antinozzi C, et al. The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One 2013;8:e77745.PubMedPubMedCentralCrossRef
120.
121.
Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol 2014;26:704-711.PubMedCrossRef
122.
Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009;10:178-184.PubMedCrossRef
123.
Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2013;6:CD004760.PubMed
124.
Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-345.PubMedCrossRef
125.
126.
Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41:185-190.PubMed
127.
Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013;48:477-483.PubMedCrossRef
128.
Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61.PubMedPubMedCentralCrossRef
129.
Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010;62:1328-1334.CrossRef
130.
Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45:1302-1304.PubMedCrossRef
131.
Zschuntzsch J, Voss J, Creus K, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle. Arthritis Rheum 2012;64:4094-4103.PubMedCrossRef
132.
Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61:260-262.PubMedCrossRef
133.
Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 2012;30:838-842.PubMed
134.
Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-1570.CrossRef
135.
Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718-720.CrossRef
136.
Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66:S123-S124.PubMedCrossRef
137.
Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013;334:123-125.PubMedCrossRef
138.
Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial. Ann Rheum Dis 2013;72:A164.CrossRef
139.
Allenbach Y, Rigolet A, Guiguet M, et al. Efficacy of rituximab for the treatment of refractory inflammatory myopathies associated with anti-histidyl-tRNA synthetase antibodies (the FORCE Jo1 Study). Abstract Number 220, American College of Rheumatology Meeting, 2012
140.
Coyle K, Pokrovnichka A, French K. A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 2008;58:S293
141.
Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014;83:1-8.CrossRef
142.
Dorph C, Dastmalchi M, Alexanderson H, et al. Anakinra in patients with refractory idiopathic inflammatory myopathies. Arthritis Rheum 2009;60(Suppl.):589.
143.
Barohn, RJ, Harbelin L, Kissel JT, King W, McVey AL, Saperstein DS. Pilot trial of etanercept in the treatment of sporadic inclusion-body myositis Neurology 2006;66(Suppl. 2):S123-S124.PubMedCrossRef
144.
Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73:256-262.PubMedCrossRef
Metadata
Title
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective
Authors
Merrilee Needham
Frank L. Mastaglia
Publication date
01-01-2016
Publisher
Springer US
Published in
Neurotherapeutics / Issue 1/2016
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0394-2

Other articles of this Issue 1/2016

Neurotherapeutics 1/2016 Go to the issue

Review

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Publisher's Erratum

Erratum to: Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid

Erratum

Erratum to: Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection

Editorial

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future

Review

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

Review

Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis